Avelumab and Merkel Cell Carcinoma: Examining Causation in Occupational Exposure

From General Health Information to Occupational Exposure Concerns

Legacy health information resources have long provided the public with structured, accessible data on general wellness and disease prevention. These repositories, often organized by condition or symptom, serve as foundational tools for understanding broad health risks. However, the transition from general health awareness to specific occupational exposure concerns requires a shift in focus. In the context of mass production environments, workers may encounter therapeutic agents not as patients, but as part of industrial processes. One such agent is Avelumab, a monoclonal antibody used in oncology. While its clinical application is well-documented, the potential for occupational exposure during manufacturing or handling introduces a distinct risk profile. This pivot moves the inquiry from a patient-centered understanding of drug effects to an occupational health perspective, where the primary concern is not therapeutic outcome but unintended exposure. The central question thus becomes whether Avelumab exposure in a workplace setting could be associated with the development of Merkel Cell Carcinoma, a rare skin cancer. This reframing necessitates examining exposure pathways, dose levels, and latency periods relevant to industrial hygiene, rather than clinical efficacy or patient outcomes.

Clinical Presentation and Diagnosis of Merkel Cell Carcinoma

Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/). It is characterized by rapid growth and a high propensity for metastasis. MCC is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus (https://pubmed.ncbi.nlm.nih.gov/35877101/). The incidence of MCC is increasing, and the disease is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Diagnosis typically involves histopathological examination of biopsy specimens, with immunohistochemical staining for neuroendocrine markers such as cytokeratin 20 and synaptophysin. Clinical presentation often includes a rapidly enlarging, painless, firm, red or purple nodule on sun-exposed skin, most commonly on the head, neck, or extremities.

Avelumab Pharmacology and Reported Adverse Effects

Avelumab (Bavencio®) is a fully human IgG1 monoclonal antibody directed against programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It functions as an immune checkpoint inhibitor, blocking the interaction between PD-L1 on tumor cells and PD-1 on T cells, thereby enhancing anti-tumor immune responses. Avelumab has been approved in the USA, the EU, and Japan for the treatment of metastatic MCC, and it is the first therapeutic agent specifically approved for this indication, independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). Approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). Reported adverse effects of avelumab include immune-related adverse events (irAEs) due to overactivation of the immune system (https://pubmed.ncbi.nlm.nih.gov/31543781/). These can include conditions such as sarcoidosis, as described in a case of hypercalcaemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab (https://pubmed.ncbi.nlm.nih.gov/31543781/). In that case, hypercalcaemia was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). Other irAEs may include dermatitis, colitis, hepatitis, pneumonitis, and endocrinopathies.

Mechanistic Pathways Linking Avelumab to Merkel Cell Carcinoma

The query asks whether avelumab causes MCC. The evidence indicates that avelumab is a treatment for MCC, not a cause. The mechanistic pathway of avelumab involves blocking PD-L1, which is expressed on MCC cells, to enhance T-cell-mediated killing of tumor cells. There is no evidence in the provided snippets that avelumab induces or causes MCC. Instead, avelumab is used to treat MCC, and response rates to PD-1/PD-L1 inhibition in metastatic MCC can be up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). For avelumab-refractory patients, efficient and safe treatment options are lacking, though combined ipilimumab plus nivolumab has shown activity in such patients (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/).

Adequacy of Warnings and Causation Considerations

The evidence does not provide specific information on the adequacy of warnings regarding avelumab and MCC. However, given that avelumab is approved specifically for the treatment of metastatic MCC, it is reasonable to infer that prescribing information and patient materials include warnings about potential adverse effects, including irAEs, and the need for monitoring. The evidence does not suggest that avelumab causes MCC; rather, it is a therapeutic agent for the disease. For patients with MCC, the question of causation by avelumab is not supported by the evidence. Avelumab is used to treat MCC, and its use is associated with potential benefits, such as durable responses, and risks, such as irAEs. Patients who experience progression on avelumab may be considered for alternative therapies, such as combined ipilimumab plus nivolumab, which has shown activity in avelumab-refractory MCC (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). Causation considerations should focus on the underlying disease and its risk factors, such as ultraviolet light exposure and Merkel cell polyoma virus, rather than on avelumab as a cause. The evidence does not document a timeline between avelumab exposure and harm in the sense of causing MCC. Instead, it documents timelines for treatment response and adverse events. For example, in the JAVELIN Merkel 200 trial, responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). In the case of sarcoidosis reactivation, hypercalcaemia occurred during treatment with avelumab and was managed with corticosteroids (https://pubmed.ncbi.nlm.nih.gov/31543781/). The evidence does not support a causal link between avelumab and the development of MCC.

Conclusion

Based on the provided evidence, avelumab does not cause Merkel cell carcinoma. Instead, it is an approved treatment for metastatic MCC, with demonstrated efficacy in a subset of patients. The evidence highlights the role of avelumab as a PD-L1 inhibitor that enhances anti-tumor immune responses, and it documents the occurrence of immune-related adverse events during treatment. There is no evidence to suggest that avelumab induces or causes MCC. Patients and clinicians should be aware of the benefits and risks of avelumab therapy, including the potential for irAEs, and should consider alternative treatments for avelumab-refractory disease.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

Does Avelumab cause Merkel Cell Carcinoma?

No, based on current evidence, Avelumab does not cause Merkel Cell Carcinoma (MCC). In fact, Avelumab is an FDA-approved treatment for metastatic MCC. It works by blocking PD-L1 to enhance the immune system's ability to kill tumor cells. There is no evidence that Avelumab induces or causes MCC; rather, it is used to treat the disease.

What are the known adverse effects of Avelumab?

Avelumab can cause immune-related adverse events (irAEs) due to overactivation of the immune system. These may include dermatitis, colitis, hepatitis, pneumonitis, endocrinopathies, and reactivation of conditions like sarcoidosis. In a reported case, hypercalcaemia secondary to sarcoidosis reactivation was managed with corticosteroids, and Avelumab therapy was continued safely (https://pubmed.ncbi.nlm.nih.gov/31543781/).

What is the prognosis for patients with Merkel Cell Carcinoma treated with Avelumab?

In the JAVELIN Merkel 200 trial, approximately one-third of patients with chemotherapy-refractory metastatic MCC achieved confirmed objective responses with Avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Response rates to PD-1/PD-L1 inhibition in metastatic MCC can be up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, about 50% of patients progress on therapy, and alternative treatments like combined ipilimumab plus nivolumab have shown activity in Avelumab-refractory cases (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.